ABUS vs PAYC · P/E 5.4, rev $6.2M vs P/E 33, rev $1.88B
Arbutus Biopharma Corp (ABUS) versus Paycom Soft (PAYC) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Paycom Soft (PAYC) is a software - application company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported PAYC revenue for 2024-12-31 was $1.88B. Net income was $502.0M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
Not investment advice. Open the ABUS and PAYC stock pages for the full models.
Not investment advice.